scholarly journals Increased body fat mass reduces the association between fructosamine and glycated hemoglobin in obese type 2 diabetes patients

2020 ◽  
Author(s):  
Bruno Vergès ◽  
Alexia Rouland ◽  
Sabine Baillot‐Rudoni ◽  
Marie‐Claude Brindisi ◽  
Laurence Duvillard ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Fat ◽  
Fat Mass ◽  
Glycated Hemoglobin ◽  
Body Fat Mass ◽  
Diabetes Patients

Osteoprotegerin is associated with markers of atherosclerosis and body fat mass in type 2 diabetes patients

2011 ◽  
Vol 147 (2) ◽  
pp. 335-336 ◽  
Author(s):  
Małgorzata Waluś-Miarka ◽  
Barbara Katra ◽  
Danuta Fedak ◽  
Danuta Czarnecka ◽  
Przemysław Miarka ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Fat ◽  
Fat Mass ◽  
Body Fat Mass ◽  
Diabetes Patients

1019-P: Glucagon-Like Peptide-1 Receptor Agonists Predominantly Reduce Body Fat Mass in Patients with Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1019-P
Author(s):  
YUKI FUJITA ◽  
SODAI KUBOTA ◽  
HITOSHI KUWATA ◽  
DAISUKE YABE ◽  
YOSHIYUKI HAMAMOTO ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Fat ◽  
Fat Mass ◽  
Body Fat Mass ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass

2002 ◽  
Vol 39 (3) ◽  
pp. 105-110 ◽  
Author(s):  
S. Fischer ◽  
M. Hanefeld ◽  
S. M. Haffner ◽  
C. Fusch ◽  
U. Schwanebeck ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Fat ◽  
Fat Mass ◽  
Body Fat Mass ◽  
Serum Leptin ◽  
Insulin Resistant

scholarly journals Association of body fat mass with left ventricular longitudinal myocardial systolic function in type 2 diabetes mellitus

2020 ◽  
Vol 75 (2) ◽  
pp. 189-195 ◽  
Author(s):  
Yutaka Hatani ◽  
Hidekazu Tanaka ◽  
Yasuhide Mochizuki ◽  
Makiko Suto ◽  
Shun Yokota ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Fat ◽  
Fat Mass ◽  
Systolic Function ◽  
Left Ventricular ◽  
Body Fat Mass

scholarly journals Serum Fibroblast Growth Factor 21 Levels Are Positively Associated with Metabolic Syndrome in Patients with Type 2 Diabetes

2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Ruo-Yao Gao ◽  
Bang-Gee Hsu ◽  
Du-An Wu ◽  
Jia-Sian Hou ◽  
Ming-Chun Chen
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Body Fat ◽  
Fat Mass ◽  
Density Lipoprotein ◽  
Fibroblast Growth Factor 21 ◽  
Body Fat Mass ◽  
Fibroblast Growth

Background. Fibroblast growth factor 21 (FGF21) acts as a potent metabolic regulator. Serum FGF21 levels were significantly higher in obesity and type 2 diabetes mellitus (T2DM) populations. The aim of this study was to evaluate the relationship between serum FGF21 levels and metabolic syndrome (MetS) in T2DM patients. Methods. Fasting blood samples were obtained from 126 T2DM patients. MetS and its components were defined according to the diagnostic criteria from the International Diabetes Federation. Serum FGF21 concentrations were measured using a commercially available enzyme-linked immunosorbent assay. Results. Among these patients, 84 (66.7%) had MetS. Female gender, hypertension, systolic blood pressure (SBP), diastolic blood pressure (DBP), waist circumference (WC), body weight (BW), body mass index (BMI), body fat mass, fasting glucose, glycated hemoglobin level (HbA1c), triglyceride level (TG), urine albumin-to-creatinine ratio (UACR), insulin level, homeostasis model assessment of insulin resistance (HOMA-IR), and FGF21 levels were higher, whereas high-density lipoprotein cholesterol level (HDL-C) and estimated glomerular filtration rate (eGFR) were lower in DM patients with MetS. Univariate linear analysis revealed that hypertension, BMI, WC, body fat mass, SBP, DBP, logarithmically transformed TG (log-TG), low-density lipoprotein cholesterol (LDL-C) level, log-glucose, log-creatinine, log-UACR, log-insulin, and log-HOMA-IR positively correlated, whereas HDL-C and eGFR negatively correlated with serum FGF21 levels in T2DM patients. Multivariate forward stepwise linear regression analysis revealed that body fat mass (adjusted R2 change = 0.218; P=0.008) and log-TG (adjusted R2 change = 0.036; P<0.001) positively correlated, whereas eGFR (adjusted R2 change = 0.033; P=0.013) negatively correlated with serum FGF21 levels in T2DM patients. Conclusions. This study showed that higher serum FGF21 levels were positively associated with MetS in T2DM patients and significantly positively related to body fat mass and TG but negatively related to eGFR in these subjects.

scholarly journals Eating architecture in adults at increased risk of type 2 diabetes: associations with body fat and glycaemic control

2021 ◽  
pp. 1-28
Author(s):  
Lijun Zhao ◽  
Xiao Tong Teong ◽  
Kai Liu ◽  
Bo Liu ◽  
Yohannes A Melaku ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycaemic Control ◽  
Body Fat ◽  
Fat Mass ◽  
Time Lag ◽  
Body Fat Mass ◽  
Linear Regression Models ◽  
Increased Risk ◽  
Meal Consumption

Abstract Eating architecture is a term that describes meal frequency, meal timing, and meal size and the daily variation in each of these. The aim of this study was to determine the relationship between components of eating architecture on body fat and markers of glycaemic control in healthy adults at increased risk of type 2 diabetes (T2DM). Participants (N=73, 39 males, age 58.8 [8.1] years, BMI 33.4 [4.4] kg/m2) recorded food intake and wore accelerometers and continuous glucose monitors (CGM) for 7-14 days under free-living conditions. Body fat and glycated haemoglobin (HbA1c) were also measured. The mean and day-to-day variation (calculated as the standard deviation during the monitoring period) of each component of eating architecture were calculated. Multivariable linear regression models were constructed for three separate outcome variables (body fat mass, mean CGM glucose, and HbA1c) for each component of eating architecture before and after adjustment for confounders. Higher variability in the time of first meal consumption was associated with increased body fat mass after adjusting for confounders (β=0.227, 95% CI: 0.019, 0.434, p=0.033). Increased variability in the time lag from waking to first meal consumption was also positively associated with increased HbA1c after adjustment (β=0.285, 95%CI: 0.040, 0.530, p=0.023). Low day-to-day variability in first meal consumption was associated with lower body fat and improved glucose control in adults at increased risk of T2DM. Routine consumption of meals may optimise temporal regulation to anticipate and respond appropriately to a glucose challenge.

ASSOCIATION OF BODY FAT MASS WITH LEFT VENTRICULAR MYOCARDIAL SYSTOLIC LONGITUDINAL DYSFUNCTION IN TYPE 2 DIABETES MELLITUS

2019 ◽  
Vol 73 (9) ◽  
pp. 1498
Author(s):  
Yutaka Hatani ◽  
Hidekazu Tanaka ◽  
Yasuhide Mochizuki ◽  
Makiko Suto ◽  
Hiroki Takada ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Fat ◽  
Fat Mass ◽  
Left Ventricular ◽  
Body Fat Mass

scholarly journals Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity

2021 ◽  
Vol 4 (1) ◽  
pp. e2033457 ◽  
Author(s):  
Steven B. Heymsfield ◽  
Laura A. Coleman ◽  
Ram Miller ◽  
Daniel S. Rooks ◽  
Didier Laurent ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Fat ◽  
Fat Mass ◽  
Body Fat Mass ◽  
Diabetes And Obesity
Sign in / Sign up

Export Citation Format

Share Document